Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers

PURPOSE: Evogliptin (DA-1229) is a novel, potent, and selective dipeptidyl peptidase IV (DPP-IV) inhibitor in clinical development for the treatment of type 2 diabetes mellitus. This study aimed to investigate the pharmacokinetic and pharmacodynamic profiles and tolerability of evogliptin after repe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Gu, Namyi, Park, Min Kyu, Kim, Tae-Eun, Bahng, Mi Young, Lim, Kyoung Soo, Cho, Sang-Heon, Yoon, Seo Hyun, Cho, Joo-Youn, Jang, In-Jin, Yu, Kyung-Sang
Format: Artigo
Sprache:Inglês
Veröffentlicht: Dove Medical Press 2014
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4199987/
https://ncbi.nlm.nih.gov/pubmed/25336915
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S65678
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge